GlassScriptPhysician profile
Susan A Ambruso
NPI 1891917894
$2,096.92
in general payments reported to CMS, 2019-2025
12 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $280 · 2022: $251 · 2023: $246 · 2024: $898 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,565.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $320.63 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $293.40 | 2022-2024 | Fruzaqla |
| Jazz Pharmaceuticals INC. | $279.31 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $247.17 | 2021-2023 | |
| Janssen Biotech, INC. | $145.63 | 2024 | Rybrevant |
| Servier Pharmaceuticals LLC | $133.36 | 2024 | |
| Janssen Scientific Affairs, LLC | $130.81 | 2024 | Rybrevant |
| Amgen INC. | $127.57 | 2024 | |
| Adaptive Biotechnologies Corporation | $118.05 | 2025 | Clonoseq |
| Merck Sharp & Dohme LLC | $108.50 | 2025 | Keytruda |
| Glaxosmithkline, LLC. | $101.60 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $90.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Ambruso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.